Across TCGA pan-cancer cohorts, LILRB3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LILRB3 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LILRB3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated LILRB3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KIRC, and BLCA are the cancer types where LILRB3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.967	0.617	.008	34	view →
KIRC	OS	Median	II,III,IV	0.221	0.789	.016	30	view →
BLCA	OS	Median	III,IV	0.254	0.688	.001	18	view →
STAD	OS	Median	III,IV	0.196	0.632	.026	6	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: LILRB3 tumor-vs-normal RNA expression · all LILRB3 data types